How to Get Synagis (Palivizumab) Covered by Cigna in Florida: Provider Partnership Guide
Answer Box: Getting Synagis Covered by Cigna in Florida
Synagis (palivizumab) requires prior authorization from Cigna for high-risk infants meeting specific criteria. The fastest path to approval: (1) Confirm your child meets AAP-approved risk factors (premature birth <29 weeks, congenital heart disease, chronic lung disease), (2) Have your pediatric specialist submit Cigna's PA form with detailed medical records to Express Scripts at (855) 840-1678, and (3) If denied, file an internal appeal within 180 days. Start today by gathering your child's medical records and scheduling with a pediatric cardiologist or pulmonologist if needed.
Table of Contents
- Coverage Requirements at a Glance
- Step 1: Set Your Goal - Understanding What Approval Requires
- Step 2: Prepare for Your Provider Visit
- Step 3: Build Your Evidence Kit
- Step 4: Work with Your Doctor on the Medical Necessity Letter
- Step 5: Support Your Provider During Peer-to-Peer Review
- Step 6: Document Everything After Your Visit
- Step 7: Practice Respectful Persistence
- Common Denial Reasons & How to Fix Them
- Appeals Process for Cigna in Florida
- Frequently Asked Questions
- When to Escalate Beyond Cigna
- Sources & Further Reading
Coverage Requirements at a Glance
| Requirement | What It Means | Where to Find It |
|---|---|---|
| Prior Authorization | Required for all Synagis prescriptions | Cigna PA Policy |
| High-Risk Criteria | Premature birth <29 weeks, CHD, chronic lung disease | AAP Guidelines |
| Age Limits | Generally <24 months for most conditions | Cigna Coverage Policy |
| Season Limits | Maximum 5 doses per RSV season | FDA Label |
| Specialist Required | Pediatric cardiology or pulmonology letter | Express Scripts PA Requirements |
| Appeals Deadline | 180 days from denial notice | Florida Insurance Law |
Step 1: Set Your Goal - Understanding What Approval Requires
Getting Synagis covered by Cigna requires proving your child meets strict high-risk criteria and that no alternative treatments are available. Your partnership with your provider is essential - they hold the medical expertise, but you can streamline the process by coming prepared.
Cigna covers Synagis only for infants who meet American Academy of Pediatrics guidelines for high-risk RSV prevention:
- Premature infants born before 29 weeks gestation
- Chronic lung disease of prematurity requiring oxygen, diuretics, or steroids in the past 6 months
- Hemodynamically significant congenital heart disease requiring surgery or heart failure medications
- Severe immunocompromise or certain other complex medical conditions
Important Note: As of 2025, Synagis is being phased out in favor of newer RSV prevention medications like Beyfortus (nirsevimab). Your doctor must document that these newer options aren't available or appropriate for your child.
Step 2: Prepare for Your Provider Visit
Come to your appointment with a clear timeline and documentation. This preparation helps your doctor write a stronger medical necessity letter and reduces the chance of delays.
Bring This Information:
- Birth history: Gestational age, birth weight, NICU stay details
- Current symptoms: Breathing difficulties, feeding problems, growth concerns
- Treatment timeline: All medications tried, hospitalizations, oxygen use
- Side effects experienced: From any previous treatments or interventions
- Functional impact: How RSV risk affects daily life, development, feeding
Questions to Ask Your Provider:
- "Does my child meet Cigna's criteria for Synagis coverage?"
- "What specific documentation do you need from me?"
- "Can you submit the prior authorization today, or what's the timeline?"
- "If we're denied, will you be available for a peer-to-peer review call?"
Step 3: Build Your Evidence Kit
Your provider needs comprehensive documentation to support the prior authorization. Gather these materials before your visit:
Medical Records to Collect:
- Hospital discharge summaries from NICU or cardiac surgery
- Echocardiogram reports (for heart conditions)
- Pulmonary function tests or chest X-rays
- Current medication lists with dosages
- Growth charts showing failure to thrive (if applicable)
Insurance Documentation:
- Current Cigna member ID card
- Summary of benefits (to confirm specialty drug coverage)
- Any previous denial letters for RSV prevention
Clinical Notes to Request:
- Recent visit notes mentioning RSV risk
- Specialist consultations (cardiology, pulmonology)
- Emergency department visits for respiratory issues
From Our Advocates: "One family we worked with was initially denied because their cardiologist's letter didn't specify that the child's heart defect was 'hemodynamically significant' - the exact language Cigna requires. After adding that specific phrase and attaching the surgical report, the appeal was approved within a week."
Step 4: Work with Your Doctor on the Medical Necessity Letter
The medical necessity letter is your strongest tool for approval. Help your provider include these essential elements:
Required Components:
- Clear diagnosis with ICD-10 codes
- Specific risk factors that match Cigna's criteria exactly
- Prior treatment history and why alternatives aren't suitable
- Clinical rationale for Synagis specifically
- Risks of delayed treatment for your child's condition
Template Language to Suggest:
"I am requesting prior authorization for Synagis (palivizumab) for [Child's Name], a [gestational age] week former premature infant now [current age] with [specific diagnosis]. This patient meets Cigna's coverage criteria due to [specific risk factor from policy]. The patient has NOT received Beyfortus (nirsevimab) this RSV season and this medication is not available/appropriate because [reason]. Without RSV prophylaxis, this child faces significant risk of hospitalization and respiratory failure."
Supporting Evidence to Include:
- FDA prescribing information for dosing justification
- AAP policy statements on RSV prevention
- Relevant studies from pediatric cardiology or pulmonology literature
Counterforce Health helps families and providers create targeted, evidence-backed appeals that directly address payer criteria like Cigna's specific requirements for Synagis coverage.
Step 5: Support Your Provider During Peer-to-Peer Review
If Cigna requests a peer-to-peer review, your provider will speak directly with a Cigna medical director. You can help by:
Offering Availability Windows: "I know you're busy - would morning or afternoon work better for the peer-to-peer call? I can adjust my schedule to be available if you need any information during the call."
Preparing a Concise Case Summary: Write a one-page summary of your child's key medical facts, previous treatments, and current status. This helps your provider quickly reference important details during the call.
Key Points for Your Provider to Emphasize:
- Specific high-risk criteria your child meets
- Why newer RSV prevention options aren't suitable
- Previous hospitalizations or respiratory complications
- Current medications and ongoing medical needs
Step 6: Document Everything After Your Visit
Keep detailed records of every interaction with Cigna and your healthcare team:
What to Save:
- All prior authorization forms and submissions
- Denial letters with specific reasons cited
- Provider notes from your patient portal
- Phone call logs with Cigna customer service
- Fax confirmations for submitted documents
How to Stay Organized:
- Create a dedicated folder (physical or digital) for all Synagis-related documents
- Use your patient portal to message your provider with questions
- Take photos of insurance cards and important forms as backup
Step 7: Practice Respectful Persistence
Getting specialty drug approvals often requires multiple touchpoints. Here's how to follow up effectively:
Timeline for Updates:
- Week 1: Confirm prior authorization was submitted
- Week 2: Check status with Cigna customer service
- Week 3: If no decision, ask provider to call Cigna directly
- Beyond 3 weeks: Consider filing a complaint with Florida insurance regulators
How to Escalate Politely: "I understand these reviews take time, but my child's RSV season is approaching. Can you help me understand what's causing the delay and how we can move this forward?"
Common Denial Reasons & How to Fix Them
| Denial Reason | How to Overturn | Required Documentation |
|---|---|---|
| "Outside labeled high-risk groups" | Submit specialist letter confirming specific criteria | Cardiology/pulmonology consultation |
| "Newer alternatives available" | Document why Beyfortus isn't suitable/available | Provider attestation of unavailability |
| "Exceeding dose limits" | Clarify this is first RSV season or provide weight-based dosing | Current weight documentation |
| "Lack of specialist documentation" | Obtain pediatric cardiology or pulmonology letter | Specialist consultation within 6 months |
Appeals Process for Cigna in Florida
If your initial prior authorization is denied, you have multiple levels of appeal available under Florida law:
Level 1: Internal Appeal
- Deadline: 180 days from denial notice
- Timeline: Cigna must respond within 30 days (standard) or 72 hours (urgent)
- How to file: Cigna Appeals Form
- Required: Medical records, provider letter, denial notice
Level 2: External Review
- Deadline: 4 months after final internal denial
- Process: Independent medical review through Florida Department of Financial Services
- Cost: Free to consumers
- Contact: Florida Insurance Consumer Helpline at (877) 693-5236
For Medicare Advantage plans, the process follows federal Medicare timelines with 60-day deadlines at each level.
Frequently Asked Questions
How long does Cigna prior authorization take for Synagis? Standard reviews take up to 5 business days. Urgent requests can be expedited by calling (800) 882-4462.
What if Synagis isn't on Cigna's formulary? You can request a formulary exception with strong medical necessity documentation from your provider.
Can I appeal if my child turns 2 during the RSV season? Coverage typically continues through age 24 months for qualifying conditions, but check your specific plan details.
Does step therapy apply to Synagis? Yes, most plans require trying Beyfortus (nirsevimab) first if available and appropriate for your child's age and risk factors.
What happens if I miss the appeal deadline? You may still file for "good cause" exceptions, but it's much harder to succeed. Act quickly when you receive any denial notice.
How much does Synagis cost without insurance? Approximately $1,820 per 50mg vial as of 2025, with most children requiring 5 monthly doses during RSV season.
When to Escalate Beyond Cigna
If you've exhausted Cigna's internal appeals process, you have additional options in Florida:
Florida Department of Financial Services
- File insurance complaints online or call (877) 693-5236
- Request external review for medical necessity denials
- Free consumer assistance with insurance disputes
Medicare (for Medicare Advantage plans)
- Contact Medicare directly at 1-800-MEDICARE
- File complaints about plan administration
- Request Independent Review Entity (IRE) review
Legal Resources
- Contact Florida's legal aid organizations for complex cases
- Consider patient advocacy organizations for rare disease support
The Counterforce Health platform specializes in turning insurance denials into successful appeals by creating targeted, evidence-backed letters that directly address payer-specific requirements like Cigna's Synagis criteria.
Sources & Further Reading
- Cigna Synagis Prior Authorization Policy (PDF)
- American Academy of Pediatrics RSV Prevention Guidelines
- Florida Insurance Consumer Information
- Cigna Appeals and Exceptions Process
- Express Scripts Prior Authorization Resources
- Synagis Prescribing Information
Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider and insurance plan for the most current coverage requirements and appeal procedures. Coverage policies and procedures may change without notice.
Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.